| Product Dating |
McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days |
| Application |
Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor |
| Features and Benefits |
- Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
- Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
- All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily
- Pre-existing hypocalcemia must be corrected prior to initiating Prolia®
- Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen
- Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2
- Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton
- Protect Prolia from direct light and heat
|
- Ready-to-use formulation
- Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
- The zoledronic acid injection infusion time must not be less than 15 minutes given over a constant infusion rate
- Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
- Infusion bottle with built-in plastic hanger
- One bottle with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis
- Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP
|
|
|
- Ibandronate sodium injection is supplied as a kit containing a 3 mg/3 mL of ibandronic acid in a single-dose, clear glass, 5 mL (5 cc) prefilled syringe, a 25-gauge, 3/4 inch needle with wings, needle-stick protection device, and a 9 cm plastic tubing for attachment
|
